• Quest Diagnostics is expanding its drug screening capabilities to meet tighter global testing regulations.
• The company is rolling out oral fluid and fingerprint-based workplace testing as part of a broader service-focused offering.
• This shift targets growth opportunities in the global drug screening market beyond routine diagnostics.

Quest Diagnostics, NYSE:DGX, is leaning into drug screening as regulators worldwide push for more rigorous and flexible testing options. With a current share price of $194.16 and a 1 year return of 18.2%, the company enters this segment from a position of established scale in diagnostics rather than as a niche player.

For investors following NYSE:DGX, the move into advanced drug screening and service-oriented testing solutions presents a different angle on the business compared with traditional lab work alone. As adoption of oral fluid and fingerprint testing evolves in workplaces and new geographies, this part of the story may become more relevant to how the company balances mature and emerging revenue streams.

Stay updated on the most important news stories for Quest Diagnostics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Quest Diagnostics.

For current shareholders, Quest Diagnostics’ push into more advanced drug screening looks like an attempt to broaden its service mix beyond core lab volumes, at a time when margin pressure, insider selling of about US$12.8m over three months, and questions about valuation have raised the bar for new growth drivers. The company is leaning into stricter global regulations and new testing formats such as oral fluid and fingerprint-based workplace testing, which could help defend relationships with large employers and regulators and differentiate it from peers such as Labcorp and Sonic Healthcare. Combined with recently reported double digit full year revenue and earnings per share growth and revenue up 7.1% in the latest quarter versus the prior year, this move gives investors another data point to judge whether Quest can support its current price by adding service-oriented revenue rather than relying solely on mature diagnostic categories.

How This Fits Into The Quest Diagnostics Narrative

• The expansion into advanced drug screening supports the narrative that higher value services and broader test menus can help sustain volumes and revenue durability over time.
• It also highlights execution risk around costs and reimbursement, as building out service-heavy offerings in new markets could add complexity while analysts already flag rising operating expenses and margin pressure.
• The narrative focuses heavily on preventive and wellness testing and large acquisitions such as LifeLabs, while this pivot into workplace drug screening and emerging market regulations may not be fully reflected in those assumptions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Quest Diagnostics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts and external models have highlighted a limited margin of safety, with concerns that the shares may be overvalued relative to some intrinsic value estimates while insiders have sold US$12.8m of stock with no reported buying.
• ⚠️ Rising operating expenses and wage inflation, together with regulatory reimbursement risks such as possible pricing headwinds from Medicare policy, could weigh on margins if productivity gains from new services do not keep pace.
• 🎁 The drug screening build out taps into stricter global regulations and higher testing needs in safety sensitive sectors, which may support recurring revenue from large employers and institutions.
• 🎁 Recent 7.1% year on year revenue growth in the fourth quarter and double digit full year revenue and earnings per share growth indicate that the business is currently generating the cash flows needed to fund expansion into new service lines.

What To Watch Going Forward

From here, keep an eye on how quickly oral fluid and fingerprint-based testing win adoption with employers, and whether that translates into visible contributions to Quest Diagnostics’ revenue mix alongside core diagnostics. Watch for any change in insider trading patterns, updates to guidance that reference drug screening as a distinct growth driver, and commentary on margins as the company invests in more service-oriented offerings while competing with players such as Labcorp and Sonic Healthcare. Any signs that new testing services help offset reimbursement pressure or cost inflation will be important for investors weighing the balance between growth opportunities and the 1 key risk analysts have already flagged around the company’s financial position.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Quest Diagnostics, head to the community page for Quest Diagnostics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.